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Bcell receptor (BCR)-mediated tonic signals are important for B cell survival and development. In this issue of
Immunity, Treanor et al. (2010) show that triggering of downstream responses is kept in check with BCR
immobilization by actin.It is known that the B cell receptor (BCR)
on the surface of resting B cells transmits
a low constitutive signal in a ligand-inde-
pendent manner, and such a signal is
required for B cell survival and develop-
ment (Lam et al., 1997). This concept is
based on inducible BCR-ablation studies
together with biochemical evidence that
expression of the BCR, per se, induces
tyrosine phosphorylation (Lam et al.,
1997; Zhang et al., 1998). A requirement
for not only BCR expression but also tonic
signaling has been well supported by
the data from genetic manipulations of
the BCR signaling subunit Iga-Igb. In the
absence of the Iga cytoplasmic domain,
immature B cell development was per-
turbed. Conversely, expression of a plas-
ma membrane-targeted Iga-Igb chimeric
protein (considered a gain-of-function
mutant of Iga-Igb) in BCR-deficient (mMT-
derived) bone marrow progenitor cells
was sufficient for generating mature B
cells (for reviews; see Monroe, 2006).
So, the question has arisen about how
expression of BCR on the cell surface
generates a signal without ligand stimula-
tion. Two potential mechanisms have
been proposed previously: self-aggrega-
tion and stable constitutive oligomeriza-
tion of the BCR in the plasma membrane
and constitutive lipid-raft localization of
the BCR. Lipid rafts are known as choles-
terol- and sphingolipid-enriched mem-
brane microdomains. In this issue of
Immunity, Treanor et al. (2010) have pro-
posed an additional mechanism; namely
a BCR diffusion dynamics model.
The constitutive oligomerization model
postulates that the BCR exists in exten-
sive oligomerized states, as shown by
biochemical characterization using weak
detergents (Schamel and Reth, 2000).
However, in more quantitative studies,fluorescence resonance energy transfer
(FRET) analysis of the BCR indicated
that IgM-containing complexes exist as
monomers (Tolar et al., 2005). In support
of the lipid-raft model, which was pro-
posed as an extension of constitutive
lipid-raft localization of pre-BCR, the
BCR was also observed to be constitu-
tively localized to lipid rafts membrane
subcompartments in B cells to some
extent. This model was initially appealing
because Src-family kinase, a key sig-
naling enzyme for BCR, resides constitu-
tively within the lipid-raft compartment.
However, contradictory observations in-
dicate that this specific localization of
the BCR is not necessarily required for
B cell signaling and subsequent develop-
ment. When expressed in progenitor
B cells that were incapable of expressing
a BCR, chimeric Iga-Igb cytoplasmic do-
mains that were targeted selectively either
to nonraft or raft compartments gener-
ated equivalent frequencies of mature
B cells both in vivo and in vitro (Fuentes-
Panana´ et al., 2005).
Batista and his colleagues have re-
examined the potential mechanism by
which BCR expression generates down-
stream signaling. As a first step for ad-
dressing this question, Treanor et al.
used total internal reflection fluorescence
microscopy (TIRFM) to visualize single
BCR molecules and found that some
BCR particles were highly mobile, but
in other cases, diffusion was largely re-
stricted in the plasma membrane. A simi-
lar restricted diffusion was also observed
with IgG molecules, indicating that the
BCR has restricted steady-state diffusion
within the plasma membrane regardless
of its isotype. Then, on the basis of the
fact that the MHC class II molecule is
largely mobile in contrast to the BCR,Immunity 32,a chimeric receptor approach was taken,
indicating that the Igb cytoplasmic do-
main is responsible for restricting the
diffusion of the BCR. Because, as dis-
cussed below, restricting the BCR diffu-
sion is thought to be important for pre-
venting spontaneous BCR activation,
clarifying the underlying mechanism for
the requirement of the Igb cytoplasmic
domain would help in understanding the
balance between immunogenic versus
tolerogenic responses.
Among cellular factors for regulating
BCR diffusion, the actin cytoskeleton was
a primary candidate. Thus, Treanor et al.
examined the relationship between actin
density and BCR diffusion and found that
in actin -filament-rich regions the BCR
exhibited limited mobility, whereas BCR
diffusion was increased in actin-poor
areas. Furthermore, the BCR moved
slowly within ezrin-rich areas but was
more mobile in the ezrin-poor regions.
Given that the ezrin-radixin-moesin
(ERM) family of actin-binding proteins is
known to act as linkers between the actin
cytoskeleton and plasma membrane
proteins, these data suggest that the actin
cytoskeleton limits the BCR diffusion by
making barriers by binding to ezrin.
Then, the question becomes whether it
is the mobile or immobile BCR that partic-
ipates in generating the tonic signal. To
address this question, Treanor et al.
treated cells with pharmacological inhibi-
tors of actin. Treatment with Latrunculin
A (LatA), a reagent for disrupting actin fila-
ments, increased the proportion of rapidly
diffusing BCRs, which in turn led to the
induction of calcium signaling as well as
Erk and Akt activation. Similar results
were observed by overexpression of the
dominant-negative form of ezrin. Togeth-









Figure 1. The Actin Cytoskeleton Controls BCR Diffusion Dynamics and Signaling
BCRs in ezrin- and actin-defined network-rich regions are immobile and exist together with inhibitory
receptors and signaling molecules such as CD22 and SHP1 (left panel). In contrast, BCRs in actin
cytoskeleton-poor regions are highly mobile and have a high increased interaction with positive regulators
such as CD19 and Src-family kinase (right panel).
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Previewsin BCR diffusion mimics an initiating of the
BCR signal and that themobile BCR in the
plasma membrane in resting B cells is
probably responsible for generating the
tonic signals. From the above data, Trea-
nor et al. predicted that the reduction in
BCR diffusion evoked by deletion of
specific signaling molecules could lead
to defective BCR tonic signals, thereby
blocking B cell development. They exam-
ined this idea by using B cells lacking BCR
signaling molecules PLCg2 and Vav1-
Vav2 because elimination of these mole-
cules is well known to block B cell devel-
opment. Indeed, they found that IgM
diffusion was decreased in both PLCg2
and Vav1-Vav2-deficient B cells. It has
been recently shown that the PI3 kinase
pathway mediates the tonic signal and
the small G protein TC21 constitutively
associates with the BCR and recruits PI3
kinase to the BCR (Srinivasan et al.,
2009; Delgado et al., 2009). Thus, it would
be interesting to address whether the PI3
kinase pathway is also involved in regula-
tion of the actin cytoskeleton or whether
this pathway participates in the tonic
signal in an actin cytoskelton-indepen-
dent manner.
Although this study uncovers the
importance of BCR diffusion for gener-
ating tonic signals, it is at first glance144 Immunity 32, February 26, 2010 ª2010 Ehard to reconcile with the prevailing view
that actin polymerization plays a positive
role in transducing lymphocyte antigen
receptor signaling, particularly demon-
strated by TCR signaling studies. How-
ever, given that BCR crosslinking induces
rapid depolymerization followed by repo-
lymerization of F-actin (Hao and August,
2005), constraint on BCR diffusion by an
ezrin- and actin-defined network might
be released at first andmay be a prerequi-
site for initiating the signaling cascade.
Therefore, as proposed by Treanor et al.,
in resting B cells, immobile BCRs are
likely to be rendered into a dormant state,
whereas mobile BCRs have a chance to
concatenate with positive coreceptors or
positive signaling molecules such as
CD19 or Src family kinase, respectively,
thereby generating downstream signals
(Figure 1).
For tonic signals, Monroe proposed a
homeostatic equilibrium model, in which,
during the resting state, downstream
B cell responses are balanced by the
steady-state activity of BCR-associated
tyrosine kinases and phosphatases (Mon-
roe, 2006). In his model, positive regula-
tors such as CD45 interact transiently
and stochastically with the BCR, trigger-
ing activation of Src family kinase. Iga-
Igb ITAM phosphorylation and assemblylsevier Inc.of the Iga-Igb-containing signaling com-
plex would then follow. Stochastic sig-
naling at individual Iga-Igb-containing
complexes would be quickly terminated
by ITIM-containing negative coreceptors
such as CD22, which are also phosphory-
lated by Src family kinase and which can
recruit phosphatases such as SHP1 to
the complex to dephosphorylate Iga and
Igb ITAMs. Taking Monroe’s model into
account, dormant immobilized BCRs
observed by Treanor et al. might preferen-
tially coalesce with inhibitory receptors
and inhibitory signaling molecules in an
actin-filament-rich region, thereby pre-
venting spontaneous signal generation
(Figure 1). In this regard, it would be inter-
esting to know whether enhancement of
BCR diffusion dynamics can lead to path-
ological conditions such as B cell lym-
phoma and autoimmune diseases.REFERENCES
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